Table 4 Features of EHRs with embedded CDSSs on which consensus was not achieved and remained as optional in the opinions of the panelists who participated in this study
| Â | Â | Round 02 | Round 03 | Source of the item | ||||
|---|---|---|---|---|---|---|---|---|
# | Item | M | IQR | %A | M | IQR | %A | |
1 | The email address of the parent(s)/guardian(s) of the pediatric patient | 5 | 4 | 52 | 5 | 3 | 53 | I |
2 | Registration number(s) of the physicians who prescribed the medications for the patients | 4 | 5 | 45 | 4 | 4 | 43 | L |
3 | Indication(s) for which the medication(s) was (were) prescribed | 6 | 4 | 62 | 6 | 3 | 60 | B |
4 | The system should be able to support the prescriber’s decisions by providing dosing recommendations | 6 | 4 | 66 | 5 | 3 | 62 | L |
5 | The system should be able to support the prescriber’s decisions by checking compatibility between medications and suggested diluents | 6 | 3 | 62 | 6 | 4 | 67 | I |
6 | The system should be able to support the prescriber’s decisions by providing a warning when the medication prescribed is not licensed for use in pediatric patients | 6 | 4 | 62 | 6 | 3 | 60 | L |
7 | Clear instructions that all medication administrations and checking should be verified by two persons | 7 | 3 | 70 | 7 | 2 | 85 | L |
8 | Allowing search and/or providing a mode of selection (for example a drop-down menu) for all medications licensed (available) in the country including their non-proprietary names and brand (branded-generic) names | 5 | 4 | 68 | 6 | 3 | 71 | B |
9 | Ability to collect adverse reactions attributed to medication use | 4 | 4 | 41 | 5 | 3 | 46 | L |
10 | Ability to provide warnings regarding medications that need monitoring | 4 | 5 | 42 | 6 | 2 | 52 | L |
11 | Ability to provide warnings (cautions) when high alert medications are prescribed | 6 | 3 | 49 | 6 | 3 | 53 | L |
12 | Ability to report prescribing errors | 4 | 4 | 38 | 5 | 4 | 43 | L |